Clinical and radiological characteristics of two patients with osteoporosis–pseudoglioma syndrome caused by a pathogenic homozygotic variant in the LRP5 gene

Abstract

BACKGROUND: Osteoporosis–pseudoglioma syndrome (OMIM #259770) is an ultrarare autosomal recessive disease characterized by congenital or infant blindness, severe osteoporosis, and spontaneous bone fractures. The syndrome is caused by pathogenic variants in the LRP5 gene, which encodes a protein involved in the transmission of signals in the Wnt/β-catenin signaling pathway. To date, 77 pathogenic variants associated with osteoporosis–pseudoglioma syndrome have been registered in LRP5, mainly localized in the second and third beta-propeller domains of the protein, which have a high affinity for the Wnt ligand.

CLINICAL CASES: Two siblings presented with clinical manifestations of osteoporosis–pseudoglioma syndrome caused by a pathogenic homozygous missense variant c.1481G>A (p.Arg494Gln) in LRP5. The phenotype of the patients was characterized by a combination of blindness, low bone-mineral density, short stature, and fractures and deformities of long tubular bones and the spine.

DISCUSSION: The rarity of the osteoporosis–pseudoglioma syndrome and the similarity of the clinical manifestations of various skeletal disorders and their genetic heterogeneity lead to a late diagnosis and treatment.

CONCLUSIONS: We are the first to present the clinical, radiological, and genetic characteristics of two siblings with clinical manifestations of osteoporosis–pseudoglioma syndrome. Its rarity necessitates detailed description of the clinical and genetic characteristics of this syndrome. Molecular genetic testing is an important part of a comprehensive diagnosis.

Keywords

osteoporosis–pseudoglioma syndrome / bone fractures / low bone-mineral density / LRP5 gene

References

[1] Orphanet [Internet]. Osteoporosis pseudoglioma syndrome [cited 2023 Nov 8]. Available from: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2788

[2] Orphanet [Internet]. Osteoporosis pseudoglioma syndrome [дата обращения 08.11.2023]. Доступ по ссылке: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=en&Expert=2788

[3] Unger S,Ferreira CR , Mortier GR, et al. Nosology of genetic skeletal disorders: 2023 revision. Am J Med Genet A. 2023;191(5):1164–1209. DOI: 10.1002/ajmg.a.63132

[4] Unger S., Ferreira C.R., Mortier G.R., et al. Nosology of genetic skeletal disorders: 2023 revision // Am. J. Med. Genet. A. 2023. Vol. 191A. No. 5. P. 1164–1209. DOI: 10.1002/ajmg.a.63132.

[5] Bianchine JW, Briard-Guillemot ML, Maroteaux P, et al. Generalized osteoporosis with bilateral pseudoglioma – an autosomal recessive disorder of connective tissue: report of three families – review of the literature. Am J Hum Genet. 1972,24:34A.

[6] Bianchine J.W., Briard-Guillemot M.L., Maroteaux P., et al. Generalized osteoporosis with bilateral pseudoglioma – an autosomal recessive disorder of connective tissue: report of three families – review of the literature // Am. J. Hum. Genet. 1972. Vol. 24.

[7] Neuhäuser G, Kaveggia EG, Opitz JM. Autosomal recessive syndrome of pseudogliomantous blindness, osteoporosis and mild mental retardation. Clin Genet. 1976;9(3):324–332. DOI: 10.1111/j.1399-0004.1976.tb01581.x

[8] Neuhäuser G., Kaveggia E.G., Opitz J.M. Autosomal recessive syndrome of pseudogliomatous blindness, osteoporosis and mild mental retardation // Clin. Genet. 1976. Vol. 9. No. 3. P. 324–332. DOI: 10.1111/j.1399-0004.1976.tb01581.x

[9] De Paepe A, Leroy JG, Nuytinck L, et al. Osteoporosis-pseudoglioma syndrome. Am J Med Genet. 1993;45(1):30–37. DOI: 10.1002/ajmg.1320450110

[10] De Paepe A., Leroy J.G., Nuytinck L., et al. Osteoporosis – pseudoglioma syndrome // Am. J. Med. Genet. 1993. Vol. 45. No. 1. P. 30–37. DOI: 10.1002/ajmg.1320450110

[11] Gong Y, Slee RB, Fukai N, et al.; Osteoporosis-Pseudoglioma Syndrome Collaborative Group. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107(4):513–523. DOI: 10.1016/s0092-8674(01)00571-2

[12] Gong Y., Slee R.B., Fukai N., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development // Cell. 2001. Vol. 107. No. 4. P. 513–523. DOI: 10.1016/s0092-8674(01)00571-2

[13] Boyden LM, Mao J, Belsky J, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346(20):1513–1521. DOI: 10.1056/NEJMoa013444

[14] Boyden L.M., Mao J., Belsky J., et al. High bone density due to a mutation in LDL-receptor-related protein 5 // N. Engl. J. Med. 2002. Vol. 346. No. 4. P. 1513–1521. DOI: 10.1056/NEJMoa013444

[15] Marques-Pinheiro A, Levasseur R, Cormier C, et al. Novel LRP5 gene mutation in a patient with osteoporosis-pseudoglioma syndrome. Joint Bone Spine. 2010;77(2):151–153. DOI: 10.1016/j.jbspin.2009.11.013

[16] Marques-Pinheiro A., Levasseur R., Cormier C., et al. Novel LRP5 gene mutation in a patient with osteoporosis-pseudoglioma syndrome // Joint Bone Spine. 2010. Vol. 77. No. 2. P. 151–153. DOI: 10.1016/j.jbspin.2009.11.013

[17] Laine CM, Chung BD, Susic M, et al. Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG). Eur J Hum Genet. 2011;19(8):875–881. DOI: 10.1038/ejhg.2011.42

[18] Laine C.M., Chung B.D., Susic M., et al. Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG) // Eur. J. Hum. Genet. 2011. Vol. 19. No. 8. P. 875–881. DOI: 10.1038/ejhg.2011.42

[19] Takagi J, Yang Y, Liu JH, et al. Complex between nidogen and laminin fragments reveals a paradigmatic beta-propeller interface. Nature. 2003;424(6951):969–974. DOI: 10.1038/nature01873

[20] Takagi J., Yang Y., Liu J.H., et al. Complex between nidogen and laminin fragments reveals a paradigmatic β-propeller interface // Nature. 2003. Vol. 424. No. 6951. P. 969–974. DOI: 10.1038/nature01873

[21] Richards S, Aziz N, Bale S, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–424. DOI: 10.1038/gim.2015.30

[22] Richards S., Aziz N., Bale S., et al.; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology // Genet. Med. 2015. Vol. 17. No. 5. P. 405–424. DOI: 10.1038/gim.2015.30

[23] Levasseur R, Lacombe D, de Vernejoul MC. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders. Joint Bone Spine. 2005;72(3):207–214. DOI: 10.1016/j.jbspin.2004.10.008

[24] Levasseur R., Lacombe D., De Vernejoul M.C. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders // Joint Bone Spine. 2005. Vol. 72. No. 3. P. 207–214. DOI: 10.1016/j.jbspin.2004.10.008

[25] Biha N, Ghaber SM, Hacen MM, et al. Osteoporosis-pseudoglioma in a mauritanian child due to a novel mutation in LRP5. Case Rep Genet. 2016;2016. DOI: 10.1155/2016/9814928

[26] Noura Biha S.M., Ghaber M.M., Hacen C.C. Osteoporosis-pseudoglioma in a mauritanian child due to a novel mutation in LRP5 // Case Rep. Genet. 2016. Vol. 2016. DOI: 10.1155/2016/9814928

[27] Kato M, Patel MS, Levasseur R, et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J Cell Biol. 2002;157(2):303–314. DOI: 10.1083/jcb.200201089

[28] Kato M., Patel M.S., Levasseur R., et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor // J. Cell Biol. 2002. Vol. 157. No. 2. P. 303–314. DOI: 10.1083/jcb.200201089

[29] Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology. 2007;148(6):2635–2643. DOI: 10.1210/en.2007-0270

[30] Baron R., Rawadi G. Targeting the Wnt/β-catenin pathway to regulate bone formation in the adult skeleton // Endocrinology. 2007. Vol. 148. No. 6. P. 2635–2643. DOI: 10.1210/en.2007-0270

[31] Loh NY, Neville MJ, Marinou K, et al. LRP5 regulates human body fat distribution by modulating adipose progenitor biology in a dose- and depot-specific fashion. Cell Metab. 2015;21(2):262–273. DOI: 10.1016/j.cmet.2015.01.009

[32] Loh N.Y., Neville M.J., Marinou K., et al. LRP5 regulates human body fat distribution by modulating adipose progenitor biology in a dose- and depot-specific fashion // Cell Metab. 2015 Vol. 21. No. 2. P. 262–273. DOI: 10.1016/j.cmet.2015.01.009

[33] Fujino T, Asaba H, Kang MJ, et al. Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion. Proc Natl Acad Sci USA. 2003;100(1):229–234. DOI: 10.1073/pnas.0133792100

[34] Fujino T., Asaba H., Kang M.J., et al. Low-density lipoprotein receptor-related protein 5 (LRP5) is essential for normal cholesterol metabolism and glucose-induced insulin secretion // Proc. Natl. Acad. Sci. USA. 2003. Vol. 100. No. 1. P. 229–234. DOI: 10.1073/pnas.0133792100

[35] Zhong ZA, Williams BO. LRP5(low density lipoprotein receptor-related protein 5). Atlas of Genetics and Cytogenetics in Oncology and Haematology. 2011;15(3):270–275.

[36] Zhong Z.A., Williams B.O. LRP5 (low density lipoprotein receptor-related protein 5) // Atlas of Genetics and Cytogenetics in Oncology and Haematology. 2011. Vol. 15. No. 3. P. 270–275.

[37] Ai M, Heeger S, Bartels CF, et al; Osteoporosis-Pseudoglioma Collaborative Group. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am J Hum Genet. 2005;77(5):741–753. DOI: 10.1086/497706

[38] Ai M., Heeger S., Bartels C.F., et al. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome // Am. J. Hum. Genet. 2005. Vol. 77. No. 5. P. 741–753. DOI: 10.1086/497706

[39] Campos-Obando N, Oei L, Hoefsloot LH, et al. Osteoporotic vertebral fractures during pregnancy: be aware of a potential underlying genetic cause. J Clin Endocrinol Metab. 2014;99(4):1107–1111. DOI: 10.1210/jc.2013-3238

[40] Campos-Obando N., Oei L., Hoefsloot L.H., et al. Osteoporotic vertebral fractures during pregnancy: be aware of a potential underlying genetic cause // J. Clin. Endocrinol. Metab. 2014. Vol. 99. No. 4. P. 1107–1111. DOI: 10.1210/jc.2013-3238

[41] Hartikka H, Mäkitie O, Männikkö M, et al. Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children. J Bone Miner Res. 2005;20(5):783–789. DOI: 10.1359/JBMR.050101

[42] Hartikka H., Makitie O., Mannikko M., et al. Heterozygous mutations in the LDL receptor-related protein 5 (LRP5) gene are associated with primary osteoporosis in children // J. Bone Miner. Res. 2005. Vol. 20. No. 5. P. 783–789. DOI: 10.1359/JBMR.050101

[43] Saarinen A, Mäyränpää MK, Lehesjoki AE, et al. Low-density lipoprotein receptor-related protein 5 (LRP5) variation in fracture prone children. Bone. 2010;46(4):940–945. DOI: 10.1016/j.bone.2009.12.022

[44] Saarinen A., Mayranpaa M.K., Lehesjoki A.E., et al. Low-density lipoprotein receptor-related protein 5 (LRP5) variation in fracture prone children // Bone. 2010. Vol. 46. No. 4. P. 940–945. DOI: 10.1016/j.bone.2009.12.022

[45] van Meurs JB, Trikalinos TA, Ralston SH, et al; GENOMOS Study. Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. JAMA. 2008;299(11):1277–12390. DOI: 10.1001/jama.299.11.1277

[46] van Meurs J.B., Trikalinos T.A., Ralston S.H., et al.; GENOMOS Study. Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis // JAMA. 2008. Vol. 299. No. 11. P. 1277–1290. DOI: 10.1001/jama.299.11.1277

[47] Ferrari SL, Deutsch S, Baudoin C, et al. LRP5 gene polymorphisms and idiopathic osteoporosis in men. Bone. 2005;37(6):770–775. DOI: 10.1016/j.bone.2005.06.017

[48] Ferrari S.L., Deutsch S., BauDOIn C., et al. LRP5 gene polymorphisms and idiopathic osteoporosis in men // Bone. 2005. Vol. 37. No. 6. P. 770–775. DOI: 10.1016/j.bone.2005.06.017

[49] Mäkitie O, Zillikens MC. Early-onset osteoporosis. Calcif Tissue Int. 2022;110(5):546–561. DOI: 10.1007/s00223-021-00885-6

[50] Makitie O., Zillikens M.C. Early-onset osteoporosis // Calcif. Tissue Int. 2022. Vol. 110. No. 5. P. 546–561. DOI: 10.1007/s00223-021-00885-6

[51] Costantini A, Mäkitie RE, Hartmann MA, et al. Early-onset osteoporosis: rare monogenic forms elucidate the complexity of disease pathogenesis beyond type I collagen. J Bone Miner Res. 2022;37(9):1623–1641. DOI: 10.1002/jbmr.4668

[52] Costantini A., Makitie R.E., Hartmann M.A., et al. Early-onset osteoporosis: rare monogenic forms elucidate the complexity of disease pathogenesis beyond type I collagen // J. Bone Miner. Res. 2022. Vol. 37. No. 9. P. 1623–1641. DOI: 10.1002/jbmr.4668